Your participation in the treatment phase of the study will begin after completing all required assessments.

You will be randomly assigned to receive either IMVT-1402 or placebo. The placebo looks identical to the actual medication but contains no active substance.

Neither you nor your doctor will know which treatment you are receiving during the study. This is called a double-blind design and helps ensure accurate results.

You will receive the assigned treatment as a subcutaneous injection, which means the medication is injected under the skin.

The study medication is IMVT-1402, provided as a solution for injection, or placebo with the same appearance.

The specific dosage, frequency, and exact schedule of injections will be determined according to the study protocol.

Throughout the study, you will attend regular clinic visits for monitoring and assessments.

During these visits, your condition will be evaluated using several measurement tools.

The study team will assess your muscle strength, ability to perform daily activities, and any changes in your symptoms.

Your condition will be monitored to determine whether you experience a relapse, which means a worsening of your symptoms.

This will be measured using the aINCAT score, a tool that evaluates your ability to perform certain physical tasks related to arm and leg function.

The main goal of the study is to see if the treatment prevents relapse compared to placebo.

Your ability to perform daily activities will be measured using the I-RODS scale, which stands for Inflammatory Rasch-built Overall Disability Scale.

Your grip strength in your dominant hand will be measured to assess hand function.

Your muscle strength will be evaluated using the MRC-SS, which stands for Medical Research Council Sum Score. This involves testing the strength of various muscle groups.

These assessments will be performed at the beginning of the study and repeated at Week 24 to measure any changes.

At Week 24, a comprehensive evaluation will be conducted.

All the assessments performed at the beginning of the study will be repeated to measure changes in your condition.

The results will help determine the effectiveness of the treatment in preventing relapse and improving or maintaining your physical function.

During the study, you will continue receiving your current treatment for chronic inflammatory demyelinating polyneuropathy.

This may include corticosteroids, which are medications that reduce inflammation, or immunoglobulin therapy, which involves receiving antibodies to help regulate your immune system.

Your background therapy will remain at stable doses throughout the study period.

The treatment and observation period will continue as specified in the study protocol.

Final assessments will be completed to evaluate the overall results of the treatment.

Your participation in this phase of the study will conclude after all required evaluations are finished.